Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-23

    Virtual Booth

    An Enquiry

    Menu

    Deucrictibant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pharvaris Supports Deucrictibant Development in Angioedema
    Pharvaris Supports Deucrictibant Development in Angioedema

    02 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/02/3091694/0/en/Pharvaris-Presents-Data-Supporting-Ongoing-Clinical-Development-of-Deucrictibant-in-Bradykinin-Mediated-Angioedema.html

    GLOBENEWSWIRE
    02 Jun 2025
    Share Share
    Pharvaris to Present Deucrictibant Clinical Data
    Pharvaris to Present Deucrictibant Clinical Data

    19 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/19/3083864/0/en/Pharvaris-to-Present-Deucrictibant-Clinical-Data-and-Exploratory-Biomarker-Data-at-Upcoming-Congresses.html

    GLOBENEWSWIRE
    19 May 2025
    Share Share
    Pharvaris to Host Virtual R&D Call
    Pharvaris to Host Virtual R&D Call "Deucrictibant" on June 4

    12 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/12/3078953/0/en/Pharvaris-to-Host-a-Virtual-R-D-Call-Deucrictibant-Beyond-HAE-Type-1-2-on-June-4.html

    GLOBENEWSWIRE
    12 May 2025
    Share Share
    Pharvaris Reports 2024 Financial Results and Business Update
    Pharvaris Reports 2024 Financial Results and Business Update

    07 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/07/3056547/0/en/Pharvaris-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    07 Apr 2025
    Share Share
    Pharvaris: Orphan Designation Granted to Deucrictibant by EU
    Pharvaris: Orphan Designation Granted to Deucrictibant by EU

    01 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/01/3053128/0/en/Pharvaris-Announces-Orphan-Designation-Granted-to-Deucrictibant-by-the-European-Commission.html

    GLOBENEWSWIRE
    01 Apr 2025
    Share Share
    Pharvaris To Present HAE Treatment Data At HAEi Workshop
    Pharvaris To Present HAE Treatment Data At HAEi Workshop

    03 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/03/2957562/0/en/Pharvaris-Announces-Data-Highlighting-Deucrictibant-for-the-Treatment-of-HAE-to-be-Presented-at-the-2024-HAEi-Global-Leadership-Workshop.html

    GLOBENEWSWIRE
    03 Oct 2024
    Share Share